News | FFR Technologies | July 09, 2020

Acist Launches New Advance in FFR Microcatheters

The Acist Navvus II Rapid Exchange FFR MicroCatheter delivers even more flexibility and a streamlined crossing profile to assess complicated lesions

The Acist Navvus II Rapid Exchange FFR MicroCatheter delivers even more flexibility and a streamlined crossing profile to assess complicated lesions.

The Acist Navvus II Rapid Exchange FFR MicroCatheter delivers even more flexibility and a streamlined crossing profile to assess complicated lesions.

July 9, 2020 – Acist Medical Systems Inc., a Bracco Group Company, announced the global launch of its Acist Navvus II Rapid Exchange fractional flow reserve (FFR) microcatheter, the second-generation microcatheter for use with its Acist RXi Rapid Exchange FFR System.

FFR measurements provide assessment of arterial lesion severity and inform intervention strategy in both diagnosis and treatment of coronary artery disease. This latest advance delivers the same level of control, consistency and accuracy that physicians have come to expect from the original Navvus microcatheter, with valuable new enhancements. Specifically, the Acist Navvus II features a streamlined crossing contour, 28 percent more flexibility[1] and a lesion entry profile reduced by 15 percent.[2] The result is a highly deliverable microcatheter that may improve procedural efficiency.

The Navvus II Rapid Exchange MicroCatheter and its predecessor, Navvus, are the only coronary physiology products that allow the use of the physician’s 0.014 inch guidewire of choice. This market distinction may enable more efficient, faster diagnostic and post-PCI physiological assessment because wire position is maintained throughout the procedure.

Recently, the FFR-SEARCH study reported an average of 5 minutes per lesion to assess physiology following the intervention using the Acist microcatheter-based system.[3] FFR-SEARCH is a robust and independent, physician-sponsored study that utilized a prospective, all-comers registry and over 600 patients were analyzed.

“This latest advance represents the company’s continued strategic commitment to our market-defining FFR technology,” said Kristen Knox, SVP, general manager, Acist Medical Systems. “Physicians know they can rely on Navvus—and now Navvus II—to easily and quickly guide treatment decisions by invasive physiologic measurement.”

For more information https://acist.com/products/acist-rxi/navvusii-catheter/

 
References:

1. TR-07888: Compared with Navvus FFR MicroCatheter in benchtop testing. Data on file at ACIST. May not be indicative of clinical performance.

2. TR-08707: Compared with Navvus FFR MicroCatheter in benchtop testing. Data on file at ACIST. May not be indicative of clinical performance.

3. Rutger J. van Bommel, Kaneshka Masdjedi, Roberto Diletti, et al. Routine Fractional Flow Reserve Measurement After Percutaneous Coronary Intervention. The FFR-SEARCH Study. Circulation: Cardiovascular Interventions. 2019;12. Originally published 25 Apr 2019. https://doi.org/10.1161/CIRCINTERVENTIONS.118.007428. 2019;12

 

Related Content

A large subgroup analysis of the VOYAGER PAD randomized clinical trial showed neither a mortality risk nor benefit associated with the use of paclitaxel drug-coated devices (DCD) in the treatment of peripheral artery disease (PAD). The study also found that the benefit of rivaroxaban use on reducing ischemic limb and cardiovascular outcomes was consistent regardless of whether a DCD was used. #TCT2020 #TCTconnect
Feature | Cath Lab | October 18, 2020
October 18, 2020 – A large subgroup analysis of a randomized clinical trial showed neither a mortality risk nor benef
A longitudinal vessel assessment may demonstrate co-existence of multiple plaque morphologies on OCT, including superficial calcification with thrombus, healed plaque, plaque rupture, lipidic plaque with a thin capped fibrous atheroma (TCFA). #TCTconnect #TCT2020

A longitudinal vessel assessment may demonstrate co-existence of multiple plaque morphologies on OCT, including superficial calcification with thrombus, healed plaque, plaque rupture, lipidic plaque with a thin cap fibro-atheroma (TCFA).

News | Cath Lab | October 18, 2020
October 18, 2020 – Data from the...
The DISRUPT CAD III study showed intravascular lithoplasty from Shockwave Medical was effective in breaking up calcified coronary lesions. #TCT2-0

The DISRUPT CAD III study showed intravascular lithoplasty from Shockwave Medical was effective in breaking up calcified coronary lesions.

Feature | Cath Lab | October 16, 2020
October 15, 2020 — Shockwave Medical's Intravascular Lithotripsy (IVL) system to treat severely calcified coronary ar
Videos | Cath Lab | October 16, 2020
This is an example pf the Shockwave Medical Intravascular Lithotripsy (IVL) catheter system designed to break up heav
Videos | Cath Lab | July 15, 2020
Richard Botto, CVT, RCSA, chief cardiovascular technologist, division of cardiology, cardiac cath lab, offers an over
Videos | Cath Lab | July 13, 2020
The Vieussens’ arterial ring (VAR) is a connection between the conus artery and the left anterior descending (LAD) co
News | Cath Lab | July 06, 2020
July 6, 2020 — Black patients who undergo percutaneous coronary intervention (PCI) are at an increased risk for major
TCT cancels in-person meeting and goes virtual due to COVID-19
News | Cath Lab | May 27, 2020
May 27, 2020 — To ensure the health and safety of all attendees due to the ongoing COVID-19 (SARS-CoV-2) pandemic, th